Abstract:Sample hemolysis is conventionally defined as the presence of a variable amount of cell-free hemoglobin in serum or plasma. The reference (i.e. “normal”) concentration of free and measurable hemoglobin conventionally ranges between 0.22 and 0.25 g/L in serum and between 0.10 and 0.13 g/L in plasma, respectively [1]. Although no definitive evidence exists about the threshold of “pathological” hemolysis in blood samples, universal consensus has been reached that clinically significant interference for the most hemolysis-vulnerable tests (i.e. potassium, lactate dehydrogenase, aspartate aminotransferase) may start with concentrations of cell-free hemoglobin ≥0.5 g/L [2, 3]. Notably, this cut-off is also conventionally used for monitoring phlebotomy practice [4]. Although the very first studies about the impact of sample hemolysis on the quality of laboratory testing have been published more than 40 years ago [5], the frequency of hemolyzed samples remains high and generates remarkable challenges in clinical laboratory practice [6–8]. The first important issue is distinguishing between in vitro (i.e. spurious) and in vivo (i.e. hemolytic anemia) hemolysis. The differentiation between these conditions is not meaningless because the former case reflects a kaleidoscope of problems emerging throughout preanalytical sample management, thus including blood drawing, handling, transportation, storage and preparation for testing, whilst the latter mirrors a life-threatening condition, which must be timely communicated to the clinicians for adopting the most appropriate care options. According to this perspective, the second and almost consequential aspect is the need of systematically monitoring sample quality for accurate and rapid identification of hemolysis in serum or plasma, as also currently endorsed by many international accreditation standards such as the International Standards Organization (ISO) 15189:2012 and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) [9]. The most obvious consequence is that all laboratories should adopt a reliable strategy for systematic monitoring of sample quality and, moreover, for identifying the presence of, and quantifying, cell-free hemoglobin in either serum or plasma. In this issue of the journal, we publish an interesting study aimed to assess whether visual inspection of sample hemolysis by comparison with a color chart, rather than automatic assessment of serum or plasma indices, may have an impact on patient safety [10]. Interestingly, the authors concluded that nearly one-third of test results generated with manual handling of hemolyzed specimens were incorrectly managed, mainly for incorrect release of hemolysis-sensitive tests results or for unnecessary suppression of data in specimens with non-clinically significant degrees of hemolysis. In both cases, these circumstances may seriously jeopardize the managed care because release of data biased for the presence of hemolysis may then trigger inappropriate therapeutic options (i.e. administration of potassium-lowering therapy in patients with “spurious” hyperkalemia), whereas unjustified test suppression may delay both diagnosis and treatment of potentially fatal diseases (i.e. delayed or inappropriate management of arrhythmias due to underdiagnosis of in vivo hyperkalemia). Color vision is conventionally defined as the capability of distinguishing colors according to the wavelengths of light reflected, emitted or transmitted. The individual ability to identify colors and perceiving their intensity depends on multiple factors, such as the local environment and its relative light exposure, but may also relay on some genetic (i.e. Opsin gene polymorphisms), anatomic and pathological aspects, which ultimately make the eyes of one subject more capable than others (color blindness, also known as “daltonism”, is a paradigmatic example) (Figure 1) [11, 12]. All these factors make color recognition rather heterogeneous in different environments and among different individuals, thus supporting the hypothesis that visual assessment of sample quality may be highly inaccurate. Previous and highly reliable evidence has been provided that visual detection of hemolyzed samples is more inaccurate compared with automatic detection [13, 14], thus paving the way to adopting more precise and standardized approaches. The current generation of preanalytical platforms and

A Reference Chart for Clinical Biochemical Tests of Hemolyzed Serum Samples

The effect of hemolysis on 41 chemistry and immunology tests and determination of hemolysis alert index

Hemolysis on Routine Clinical Biochemical Test Results and Countermeasures

Practical recommendations for managing hemolyzed samples in clinical chemistry testing

Influence and Correction of Hemolysis on the Accuracy of Biochemical Tests

Cherry-red plasma: Beyond the assumption of hemolysis

Causes, consequences and management of sample hemolysis in the clinical laboratory

Determination of hemolysis index thresholds for biochemical tests on Siemens Advia 2400 chemistry analyzer

Visual assessment of sample quality: quo usque tandem?

Spectral Analysis Methods Based on Background Subtraction and Curvature Calculation Used in the Detection or Quantification of Hemolysis and Icterus in Blood-derived Clinical Samples

Inadvertent omission of a specimen integrity comment – an overlooked post-analytical error

Influence of haemolysis on blood biochemistry profiles in cattle

Hemolysis detection for ethanol measurement in whole blood samples before centrifugation: HemCheck device evaluation

Spectrophotometric evaluation of hemolysis in plasma by quantification of free oxyhemoglobin, methemoglobin, and methemalbumin in presence of bilirubin

Automated Measurement of Plasma Cell-Free Hemoglobin Using the Hemolysis Index Check Function

Influence of hemolysis on nucleated red blood cells count

A-162 Improved Laboratory Workflow using Automated Detection of Hemolysis, Icterus, and Lipemia for Coagulation Testing

Key Factors Influencing the Incidence of Hemolysis: A Critical Appraisal of Current Evidence

Optimization of the Hemolysis Assay for the Assessment of Cytotoxicity

Results Comparison of Biochemical Examination Between Different Blood Samples

The application of erythrocyte and reticulocyte related indices in anemia and bone marrow transplantation